Robert L. Oliver, Jr. has been a director since May 2023. From 2010 to 2020, Mr. Oliver served in a variety of senior positions at Otsuka America Pharmaceutical, Inc., a pharmaceutical company and subsidiary of Otsuka Holdings Co. Ltd., including President and Chief Executive Officer from 2016 to 2017, President and Chief Operating Officer from 2014 to 2016, Vice President of Sales and Marketing from 2010 to 2014, and as Chairman of Otsuka Canada Pharmaceutical, Inc. from 2016 to 2020. Prior to joining Otsuka, he served in a variety of senior positions at Wyeth Pharmaceuticals, a pharmaceutical company, where he also served as Senior Vice President from 2008 to 2010 and Vice President from 2005 to 2008. Mr. Oliver began his career with Johnson & Johnson, a pharmaceutical and consumer packaged goods company, where he held a variety of positions from 1989 to 2005. In addition, Mr. Oliver has served as an Executive Advisor of CELLIX Biosciences, a biopharmaceutical company, since 2018, and Hyalo Technologies, LLC, since 2017. Mr. Oliver has served as a member of the board of directors of PsyBio Therapeutics Corp., a publicly held biotechnology company, since 2021, as a member of the board of directors of Neurotez, Inc., a privately held biotechnology company, since 2017, and as a member of the board of directors of Hyalo Technologies, LLC, a privately held biotechnology and biopharmaceutical company, since 2017. Previously, he served as a member of the board of directors and as Executive Advisor of Medison Canada, an affiliate of Medison Pharma Ltd., from 2018 to 2022, and as a member of the board of directors of Immunomedics, Inc., a publicly held biotechnology company, from January 2017 until its acquisition by Gilead Sciences, Inc. in March 2017. In the not-for-profit sector, Mr. Oliver serves on the Pharma Board of Advisors at Saint Joseph’s University and on the Board of Governors of the Accreditation Council for Medical Affairs. Mr. Oliver holds a B.A. from Rutgers University and an M.B.A. from Saint Joseph’s University.
What is Bob Oliver's net worth?
The estimated net worth of Bob Oliver is at least $1.49 million as of February 25th, 2025. Oliver owns 33,514 shares of Exelixis stock worth more than $1,487,016 as of December 5th. This net worth estimate does not reflect any other assets that Oliver may own. Learn More about Bob Oliver's net worth.
How do I contact Bob Oliver?
Has Bob Oliver been buying or selling shares of Exelixis?
Bob Oliver has not been actively trading shares of Exelixis during the past quarter. Most recently, Bob Oliver sold 18,647 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a transaction totalling $694,600.75. Following the completion of the sale, the director now directly owns 33,514 shares of the company's stock, valued at $1,248,396.50. Learn More on Bob Oliver's trading history.
Who are Exelixis' active insiders?
Exelixis' insider roster includes Dana Aftab (EVP), Mary Beckerle (Director), Charles Cohen (Director), Sue Eckhardt (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), Tomas Heyman (Director), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Bob Oliver (Director), Stelios Papadopoulos (Director), Amy Peterson (CMO), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.
Are insiders buying or selling shares of Exelixis?
In the last year, insiders at the biotechnology company sold shares 25 times. They sold a total of 843,691 shares worth more than $36,692,651.16. The most recent insider tranaction occured on November, 21st when EVP Patrick J Haley sold 28,043 shares worth more than $1,194,070.94. Insiders at Exelixis own 2.8% of the company.
Learn More about insider trades at Exelixis. Information on this page was last updated on 11/21/2025.
